Bio-path Holdings Inc (NASDAQ:BPTH)’s Stock Is Buy After Less Market Selling

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Logo

The stock of Bio-path Holdings Inc (NASDAQ:BPTH) registered a decrease of 16.63% in short interest. BPTH’s total short interest was 267,200 shares in February as published by FINRA. Its down 16.63% from 320,500 shares, reported previously. With 71,700 shares average volume, it will take short sellers 4 days to cover their BPTH’s short positions. The short interest to Bio-path Holdings Inc’s float is 2.51%.

The stock decreased 2.80% or $0.058 during the last trading session, reaching $2.012. About 94,325 shares traded. Bio-Path Holdings, Inc. (NASDAQ:BPTH) has declined 85.60% since February 8, 2018 and is downtrending. It has underperformed by 85.60% the S&P500.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development firm in the United States. The company has market cap of $3.54 million. The firm develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid backbone modification intended to protect the DNA from destruction. It currently has negative earnings. The Company’s lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer.

More notable recent Bio-Path Holdings, Inc. (NASDAQ:BPTH) news were published by: Nasdaq.com which released: “Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting – Nasdaq” on December 03, 2018, also Benzinga.com with their article: “40 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” published on January 15, 2019, Stockhouse.com published: “Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock – Stockhouse” on January 17, 2019. More interesting news about Bio-Path Holdings, Inc. (NASDAQ:BPTH) were released by: Globenewswire.com and their article: “Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia – GlobeNewswire” published on August 27, 2018 as well as Globenewswire.com‘s news article titled: “Bio-Path Holdings Reports Full Year 2017 Financial Results – GlobeNewswire” with publication date: April 03, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.